Literature DB >> 28283555

Developmental, Genetic, Dietary, and Xenobiotic Influences on Neonatal Hyperbilirubinemia.

Mei-Fei Yueh1, Shujuan Chen2, Nghia Nguyen2, Robert H Tukey2.   

Abstract

Hyperbilirubinemia, caused by the accumulation of unconjugated bilirubin, is one of the most common clinical diagnoses in both premature and term newborns. Owing to the fact that bilirubin is metabolized solely through glucuronidation by UDP-glucuronosyltransferase (UGT) 1A1, it is now known that immaturity of UGT1A1, in combination with the overproduction of bilirubin during the developmental stage, acts as a bottleneck to bilirubin elimination and predisposes the infant to high total serum bilirubin levels. Although neonatal jaundice is mostly benign, excessively high levels of serum bilirubin in a small percentage of newborns can cause bilirubin-induced neurologic dysfunction, potentially leading to permanent brain damage, a condition known as kernicterus Although a large portion of hyperbilirubinemia cases in newborns are associated with hemolytic diseases, we emphasize here the impaired ability of UGT1A1 to eliminate bilirubin that contributes to hyperbilirubinemia-induced neurotoxicity in the developmental stage. As a series of hereditary UGT1A1 mutations have been identified that are associated with UGT1A1 deficiency, new evidence has verified that delayed expression of UGT1A1 during the early stages of neonatal development is a tightly controlled event involving coordinated intrahepatic and extrahepatic regulation. This review recapitulates the progress that has been made in recent years in understanding the causes and physiopathology of severe hyperbilirubinemia, investigating molecular mechanisms underlying bilirubin-induced encephalopathy, and searching for potential therapies for treating pathologic hyperbilirubinemia. Several animal models have been developed to make it possible to examine bilirubin-induced neurotoxicity from multiple directions. Moreover, environmental factors that may alleviate or worsen the condition of hyperbilirubinemia are discussed.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28283555      PMCID: PMC5416747          DOI: 10.1124/mol.116.107524

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  56 in total

1.  A randomized, triple-blind, placebo-controlled trial of prophylactic oral phenobarbital to reduce the need for phototherapy in G6PD-deficient neonates.

Authors:  Srinivas Murki; Sourabh Dutta; Anil Narang; Urmi Sarkar; Gurjeevan Garewal
Journal:  J Perinatol       Date:  2005-05       Impact factor: 2.521

2.  Current incidence of clinical kernicterus in preterm infants in Japan.

Authors:  Ichiro Morioka; Hajime Nakamura; Tsubasa Koda; Tomoyuki Yokota; Hitoshi Okada; Yoshinori Katayama; Tetsuya Kunikata; Masatoshi Kondo; Makoto Nakamura; Shigeharu Hosono; Saneyuki Yasuda; Naoki Yokoyama; Hiroshi Wada; Susumu Itoh; Masahisa Funato; Yoshitada Yamauchi; Yong Kye Lee; Masahiko Yonetani
Journal:  Pediatr Int       Date:  2015-06       Impact factor: 1.524

3.  Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation.

Authors:  Kathy Senekeo-Effenberger; Shujuan Chen; Erin Brace-Sinnokrak; Jessica A Bonzo; Mei-Fei Yueh; Upendra Argikar; Jenny Kaeding; Jocelyn Trottier; Rory P Remmel; Joseph K Ritter; Olivier Barbier; Robert H Tukey
Journal:  Drug Metab Dispos       Date:  2006-12-06       Impact factor: 3.922

4.  Kernicterus in the 21st century: frequently asked questions.

Authors:  V K Bhutani; L Johnson
Journal:  J Perinatol       Date:  2009-02       Impact factor: 2.521

5.  Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor.

Authors:  Wen Xie; Mei-Fei Yeuh; Anna Radominska-Pandya; Simrat P S Saini; Yoichi Negishi; Bobbie Sue Bottroff; Geraldine Y Cabrera; Robert H Tukey; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

6.  Brain bilirubin content is increased in P-glycoprotein-deficient transgenic null mutant mice.

Authors:  J F Watchko; M J Daood; T W Hansen
Journal:  Pediatr Res       Date:  1998-11       Impact factor: 3.756

7.  Treatment of Crigler-Najjar type 1 disease: relevance of early liver transplantation.

Authors:  Rolf Schauer; Manfred Stangl; Thomas Lang; Andreas Zimmermann; Alexander Chouker; Alexander L Gerbes; Friedrich W Schildberg; Horst G Rau
Journal:  J Pediatr Surg       Date:  2003-08       Impact factor: 2.545

8.  Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man.

Authors:  P J Bosma; J Seppen; B Goldhoorn; C Bakker; R P Oude Elferink; J R Chowdhury; N R Chowdhury; P L Jansen
Journal:  J Biol Chem       Date:  1994-07-08       Impact factor: 5.157

9.  The effect of glucocorticoid therapy in preventing early neonatal complications in preterm delivery.

Authors:  Elahe O Madarek; Naiyereh Najati
Journal:  J Perinat Med       Date:  2003       Impact factor: 1.901

10.  Effectiveness and safety of prenatal phenobarbital for the prevention of neonatal jaundice.

Authors:  T Valaes; K Kipouros; S Petmezaki; M Solman; S A Doxiadis
Journal:  Pediatr Res       Date:  1980-08       Impact factor: 3.756

View more
  7 in total

1.  NRF2-Independent Regulation of Intestinal Constitutive Androstane Receptor by the Pro-Oxidants Cadmium and Isothiocyanate in hUGT1 Mice.

Authors:  Miles Paszek; Robert H Tukey
Journal:  Drug Metab Dispos       Date:  2019-11-08       Impact factor: 3.922

2.  Humanized UGT1 Mice, Regulation of UGT1A1, and the Role of the Intestinal Tract in Neonatal Hyperbilirubinemia and Breast Milk-Induced Jaundice.

Authors:  Shujuan Chen; Robert H Tukey
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

3.  Minocycline protects neurons against glial cells-mediated bilirubin neurotoxicity.

Authors:  Changwei Zhou; Rong Sun; Chongyi Sun; Minghao Gu; Chuan Guo; Jiyan Zhang; Yansheng Du; Huiying Gu; Qingpeng Liu
Journal:  Brain Res Bull       Date:  2019-11-13       Impact factor: 4.077

4.  Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).

Authors:  Diana F Clarke; Edward P Acosta; Mae Cababasay; Jiajia Wang; Anne Chain; Hedy Teppler; Stephanie Popson; Bobbie Graham; Betsy Smith; Rohan Hazra; Kat Calabrese; Yvonne Bryson; Stephen A Spector; Jos Lommerse; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2020-05-01       Impact factor: 3.771

5.  A Non-Linear Relationship between Preoperative Total Bilirubin Level and Postoperative Delirium Incidence after Liver Transplantation.

Authors:  Ru-Yi Lu; Heng-Kai Zhu; Xiang-Yan Liu; Li Zhuang; Zhuo-Yi Wang; Yuan-Li Lei; Ting Wang; Shu-Sen Zheng
Journal:  J Pers Med       Date:  2022-01-21

6.  Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097.

Authors:  Diana F Clarke; Jos Lommerse; Edward P Acosta; Mae P Cababasay; Jiajia Wang; Stephen A Spector; Anne Chain; Elizabeth Smith; Hedy Teppler; Rohan Hazra; Kat Calabrese; Bobbie Graham; Stephanie Popson; Yvonne Bryson; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2020-12-15       Impact factor: 3.771

7.  Identification of Genetic Risk Factors for Neonatal Hyperbilirubinemia in Fujian Province, Southeastern China: A Case-Control Study.

Authors:  Jinfu Zhou; Changyi Yang; Wenbin Zhu; Shuwei Chen; Yinglin Zeng; Jing Wang; Hong Zhao; Yao Chen; Feng Lin
Journal:  Biomed Res Int       Date:  2018-09-12       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.